Multi-party efforts to promote faster access to innovative drugs for hematological tumors

Shanghai, November 7, 2021/PRNewswire/ - On the occasion of the 4th China International Import Expo, Sanofi, the world’s leading biopharmaceutical company, organized a “multi-party cohesion to promote the acceleration of the development of innovative drugs for hematological tumors”.

Launching Ceremony

Focusing on elderly hematological tumors, new treatment methods urgently need to be expanded in clinic

Statistics show that the total number of elderly people aged 60 and over in China has reached 260 million [1]

At present, multiple myeloma is the second most common malignant tumor of the blood system [2], and the incidence rate in China is about 1.

Professor Huang Xiaojun from Peking University People’s Hospital said: “In recent years, the field of multiple myeloma has made great progress in the treatment of multiple myeloma, which in turn has driven hematology clinicians to pay more attention to disease diagnosis and treatment

Professor Wu Depei of the First Affiliated Hospital of Soochow University said: “The full and all-round disease management of patients with multiple myeloma is very important.

The patient survival report is launched, accelerating the launch of innovative drugs in China

On the day of the meeting, China’s first "Multiple Myeloma Patient Quality of Life Survey Report" project led by Professor Qiu Lugui from the Institute of Hematology, Hospital of Hematology, Chinese Academy of Medical Sciences, was officially launched, which will provide in-depth understanding of patients from various aspects such as disease recognition, diagnosis, and treatment.

Gu Hongfei, the founder of the Myeloma Home of the Patient Organization, said: “Most patients with multiple myeloma are elderly people who should have spent their old age but are tortured by illness

Professor Hou Jian from Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine pointed out: “Although patients have achieved temporary remission of the disease through a combination of multiple drugs, there are still a large number of patients who have drug resistance and relapse due to disease progression

At present, benefiting from the policy of "Hong Kong and Macau Medicines and Devices", drugs that are urgently needed clinically and have been marketed in Hong Kong and Macau can be used in qualified medical institutions in the Greater Bay Area after approval

Xie Lijuan, General Manager of Sanofi Genzyme China, said: “As a multinational pharmaceutical company that has actively participated in the CIIE for four consecutive years, we are fortunate to witness the Chinese government’s vigorous promotion of medical innovation, as well as its contribution to accelerating the launch of new drugs and improving the availability of drugs.

Ms.

At present, Sarclisa® has been included in the "Beijing Pratt & Whitney Health Insurance" and the Hainan Boao "Lecheng Global Special Drug Insurance".

[1] The seventh census data

[2] Guan Nannan et al.

[3] PUPH and Peking University Health Science Centre's unpublished data (have authorized).

Source: Sanofi China